AbbVie Profit Beats Estimates as Sales of Humira Increase

AbbVie Inc., the drugmaker that split from Abbott Laboratories in January, reported third-quarter earnings that beat analysts’ estimates as sales of its top drug Humira increased. The company raised the bottom end of its full-year forecast.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.